3 active not recruiting, 3 completed, 1 withdrawn. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 3, Completed 3, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow E-7386: new trials by email Literature Review of E-7386 trials Research Report on E-7386
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants E7386 Tablet, (14C)E7386 Capsule, (14C)E7386 - Healthy Volunteers | Phase 1 | Completed | Eisai Limited | 15 | 2022-10-17 | 2023-09-21 |
| A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors E7386, Pembrolizumab, Lenvatinib - Melanoma, Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Completed | Eisai Inc. | 89 | 2021-10-27 | 2025-10-24 |
| A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants E7386 - Healthy Volunteers | Phase 1 | Withdrawn | Eisai Limited | 2021-04-09 | 2023-11-24 | |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor E7386, Lenvatinib, Doxorubicin - Endometrial Neoplasms, Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Eisai Inc. | 301 | 2019-07-11 | 2026-10-14 |
| A Food-Effect Study of E7386 in Healthy Participants E7386 - Food Effect in Healthy Participants | Phase 1 | Completed | Eisai Inc. | 17 | 2019-06-07 | 2019-11-14 |
| A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) E7386 - Solid Neoplasms, Colorectal Neoplasms | Phase 1 | Active not recruiting | Eisai Co., Ltd. | 70 | 2019-03-05 | 2026-02-27 |
| Study of E7386 in Participants With Selected Advanced Neoplasms E7386 - Advanced Neoplasms | Phase 1 | Active not recruiting | Eisai Inc. | 60 | 2017-07-27 | 2026-06-08 |
Carcinoma, Hepatocellular (4) · Colorectal Neoplasms (3) · Neoplasms (2) · Adrenocortical Carcinoma (1) · Desmoid Tumors (1) · Digestive System Neoplasms (1) · Endometrial Neoplasms (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Liver Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1)
Eisai Inc. (4) · Eisai Limited (2) · Eisai Co., Ltd. (1)
United Kingdom (4) · United States (4) · Japan (3) · Spain (2) · Canada (1) · China (1) · Denmark (1) · France (1) · Italy (1) · South Korea (1) · Taiwan (1)
PMID 40318924, PMID 40986544, PMID 42243349, PMID 42830785
2023 (2), 2016 (1)